AVTX - Avalo Therapeutics

-

$undefined

N/A

(N/A)

Avalo Therapeutics NasdaqCM:AVTX Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Location: 540 Gaither Road, Rockville, MD, 20850, United States | Website: https://www.avalotx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-80.93M

Cash

125M

Avg Qtr Burn

-13.08M

Short % of Float

2.35%

Insider Ownership

6.39%

Institutional Own.

76.24%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
AVTX-803 (CERC-803) Details
Leukocyte Adhesion Deficiency Type II

Phase 3

Data readout

AVTX-009 Details
Hidradenitis suppurativa, Autoimmune disease

Phase 2

Data readout

Phase 2

Update

Phase 2

Update

AVTX-007 (CERC-007) Details
Multiple myeloma, Adult Onset Still's Disease

Phase 1b

Update

Phase 1b

Update

AVTX-801 (CERC-801) Details
Metabolic disorder, Rare genetic disease

Failed

Discontinued

AVTX-802 (CERC-802) Details
Metabolic disorder, Rare genetic disease

Failed

Discontinued

AVTX-006 (CERC-006) Details
Lymphatic malformations

Failed

Discontinued